Literature DB >> 20022367

The use of carboxymethylcellulose gel to increase non-viral gene transfer in mouse airways.

Uta Griesenbach1, Cuixiang Meng, Raymond Farley, Marguerite Y Wasowicz, Felix M Munkonge, Mario Chan, Charlotte Stoneham, Stephanie G Sumner-Jones, Ian A Pringle, Deborah R Gill, Stephen C Hyde, Barbara Stevenson, Emma Holder, Hiroshi Ban, Mamoru Hasegawa, Seng H Cheng, Ronald K Scheule, Patrick L Sinn, Paul B McCray, Eric W F W Alton.   

Abstract

We have assessed whether viscoelastic gels known to inhibit mucociliary clearance can increase lipid-mediated gene transfer. Methylcellulose or carboxymethylcellulose (0.25-1.5%) was mixed with complexes of the cationic lipid GL67A and plasmids encoding luciferase and perfused onto the nasal epithelium of mice. Survival after perfusion with 1% CMC or 1% MC was 90 and 100%, respectively. In contrast 1.5% CMC was uniformly lethal likely due to the viscous solution blocking the airways. Perfusion with 0.5% CMC containing lipid/DNA complexes reproducibly increased gene expression by approximately 3-fold (n=16, p<0.05). Given this benefit, likely related to increased duration of contact, we also assessed the effect of prolonging contact time of the liposome/DNA complexes by delivering our standard 80 microg DNA dose over either approximately 22 or 60 min of perfusion. This independently increased gene transfer by 6-fold (n=8, p<0.05) and could be further enhanced by the addition of 0.5% CMC, leading to an overall 25-fold enhancement (n=8, p<0.001) in gene expression. As a result of these interventions CFTR transgene mRNA transgene levels were increased several logs above background. Interestingly, this did not lead to correction of the ion transport defects in the nasal epithelium of cystic fibrosis mice nor for immunohistochemical quantification of CFTR expression. To assess if 0.5% CMC also increased gene transfer in the mouse lung, we used whole body nebulisation chambers. CMC was nebulised for 1h immediately before, or simultaneously with GL67A/pCIKLux. The former did not increase gene transfer, whereas co-administration significantly increased gene transfer by 4-fold (p<0.0001, n=18). This study suggests that contact time of non-viral gene transfer agents is a key factor for gene delivery, and suggests two methods which may be translatable for use in man. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20022367      PMCID: PMC4148698          DOI: 10.1016/j.biomaterials.2009.12.005

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  29 in total

Review 1.  CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression.

Authors:  Stephen C Hyde; Ian A Pringle; Syahril Abdullah; Anna E Lawton; Lee A Davies; Anusha Varathalingam; Graciela Nunez-Alonso; Anne-Marie Green; Reto P Bazzani; Stephanie G Sumner-Jones; Mario Chan; Hongyu Li; Nelson S Yew; Seng H Cheng; A Christopher Boyd; Jane C Davies; Uta Griesenbach; David J Porteous; David N Sheppard; Felix M Munkonge; Eric W F W Alton; Deborah R Gill
Journal:  Nat Biotechnol       Date:  2008-04-27       Impact factor: 54.908

2.  Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial.

Authors:  E W Alton; M Stern; R Farley; A Jaffe; S L Chadwick; J Phillips; J Davies; S N Smith; J Browning; M G Davies; M E Hodson; S R Durham; D Li; P K Jeffery; M Scallan; R Balfour; S J Eastman; S H Cheng; A E Smith; D Meeker; D M Geddes
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

3.  Validation of nasal potential difference measurements in gut-corrected CF knockout mice.

Authors:  Uta Griesenbach; Stephen N Smith; Raymond Farley; Charanjit Singh; Eric W F W Alton
Journal:  Am J Respir Cell Mol Biol       Date:  2008-05-05       Impact factor: 6.914

4.  Expression and maturation of Sendai virus vector-derived CFTR protein: functional and biochemical evidence using a GFP-CFTR fusion protein.

Authors:  H Ban; M Inoue; U Griesenbach; F Munkonge; M Chan; A Iida; E W F W Alton; M Hasegawa
Journal:  Gene Ther       Date:  2007-09-27       Impact factor: 5.250

5.  The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects.

Authors:  S N Smith; P G Middleton; S Chadwick; A Jaffe; K A Bush; S Rolleston; R Farley; S J Delaney; B Wainwright; D M Geddes; E W Alton
Journal:  Am J Respir Cell Mol Biol       Date:  1999-01       Impact factor: 6.914

6.  Sendai virus-mediated CFTR gene transfer to the airway epithelium.

Authors:  S Ferrari; U Griesenbach; A Iida; R Farley; A M Wright; J Zhu; F M Munkonge; S N Smith; J You; H Ban; M Inoue; M Chan; C Singh; B Verdon; B E Argent; B Wainwright; P K Jeffery; D M Geddes; D J Porteous; S C Hyde; M A Gray; M Hasegawa; E W F W Alton
Journal:  Gene Ther       Date:  2007-06-28       Impact factor: 5.250

7.  Ion transport across CF and normal murine olfactory and ciliated epithelium.

Authors:  B R Grubb; T D Rogers; R C Boucher; L E Ostrowski
Journal:  Am J Physiol Cell Physiol       Date:  2009-03-25       Impact factor: 4.249

8.  Expression of CFTR from a ciliated cell-specific promoter is ineffective at correcting nasal potential difference in CF mice.

Authors:  L E Ostrowski; W Yin; P S Diggs; T D Rogers; W K O'Neal; B R Grubb
Journal:  Gene Ther       Date:  2007-07-19       Impact factor: 5.250

9.  Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets.

Authors:  Xingshen Sun; Ziying Yan; Yaling Yi; Ziyi Li; Diana Lei; Christopher S Rogers; Juan Chen; Yulong Zhang; Michael J Welsh; Gregory H Leno; John F Engelhardt
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

10.  Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs.

Authors:  Christopher S Rogers; David A Stoltz; David K Meyerholz; Lynda S Ostedgaard; Tatiana Rokhlina; Peter J Taft; Mark P Rogan; Alejandro A Pezzulo; Philip H Karp; Omar A Itani; Amanda C Kabel; Christine L Wohlford-Lenane; Greg J Davis; Robert A Hanfland; Tony L Smith; Melissa Samuel; David Wax; Clifton N Murphy; August Rieke; Kristin Whitworth; Aliye Uc; Timothy D Starner; Kim A Brogden; Joel Shilyansky; Paul B McCray; Joseph Zabner; Randall S Prather; Michael J Welsh
Journal:  Science       Date:  2008-09-26       Impact factor: 47.728

View more
  5 in total

Review 1.  Genetic therapies for cystic fibrosis lung disease.

Authors:  Patrick L Sinn; Reshma M Anthony; Paul B McCray
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

2.  Efficient production of retroviruses using PLGA/bPEI-DNA nanoparticles and application for reprogramming somatic cells.

Authors:  Eun Jin Seo; Il Ho Jang; Eun Kyoung Do; Hyo Cheon Cheon; Soon Chul Heo; Yang Woo Kwon; Geun Ok Jeong; Ba Reun Kim; Jae Ho Kim
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

3.  Therapeutic Use of 3β-[N-(N',N'-Dimethylaminoethane) Carbamoyl] Cholesterol-Modified PLGA Nanospheres as Gene Delivery Vehicles for Spinal Cord Injury.

Authors:  So-Jung Gwak; Yeomin Yun; Do Heum Yoon; Keung Nyun Kim; Yoon Ha
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

4.  The murine lung as a factory to produce secreted intrapulmonary and circulatory proteins.

Authors:  Michael C Paul-Smith; Kamila M Pytel; Jean-François Gelinas; Jenny McIntosh; Ian Pringle; Lee Davies; Mario Chan; Cuixiang Meng; Robyn Bell; Lidia Cammack; Caroline Moran; Loren Cameron; Makoto Inoue; Shu Tsugumine; Takashi Hironaka; Deborah R Gill; Stephen C Hyde; Amit Nathwani; Eric W F W Alton; Uta Griesenbach
Journal:  Gene Ther       Date:  2018-07-18       Impact factor: 5.250

5.  Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

Authors:  Uta Griesenbach; Makoto Inoue; Cuixiang Meng; Raymond Farley; Mario Chan; Nikki K Newman; Andrea Brum; Jun You; Angela Kerton; Amelia Shoemark; A Christopher Boyd; Jane C Davies; Tracy E Higgins; Deborah R Gill; Stephen C Hyde; J Alastair Innes; David J Porteous; Mamoru Hasegawa; Eric W F W Alton
Journal:  Am J Respir Crit Care Med       Date:  2012-09-06       Impact factor: 21.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.